Clinical Trials Sponsored by Watson Pharmaceuticals

Total 20865 results

Watson Pharmaceuticals

Completed

Study of Silodosin to Facilitate Passage of Urinary Stones

Urolithiasis | Ureteral Calculi | Kidney Stones

United States
Watson Pharmaceuticals

Completed

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

Prostate Cancer

United States
Watson Pharmaceuticals

Completed

Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome

Interstitial Cystitis | Painful Bladder Syndrome

United States
Watson Pharmaceuticals

Withdrawn

Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma

Leiomyomas

United States
Watson Pharmaceuticals

Completed

Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems

Hypogonadism

United States
Watson Pharmaceuticals

Completed

Effect of Two Iron Preparations on Protein in the Urine

Anemia, Iron-Deficiency | Kidney Failure, Chronic

United States
Watson Pharmaceuticals

Completed

Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients

Anemia, Iron-Deficiency | Kidney Failure, Chronic

United States, Puerto Rico
Watson Pharmaceuticals

Completed

Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome

United States
Watson Pharmaceuticals

Completed

A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition

Detrusor Hyperreflexia

United States
Watson Pharmaceuticals

Completed

DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin) (DRIVE)

Anemia, Iron-Deficiency | Hemodialysis | Kidney Failure, Chronic

United States
Watson Pharmaceuticals

Completed

Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception (Simplify)

Contraceptive Usage

United States
Watson Pharmaceuticals

Completed

Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents

Anemia, Iron-Deficiency | Kidney Failure, Chronic

United States, Puerto Rico
Watson Pharmaceuticals

Completed

Comparison Between Effects of Two Iron Preparations on Protein in the Urine

Anemia, Iron-Deficiency | Kidney Failure, Chronic

United States, Puerto Rico
Watson Pharmaceuticals

Completed

Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers

Healthy Volunteers

United States
Watson Pharmaceuticals

Completed

A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.

Interstitial Cystitis

Canada
Watson Pharmaceuticals

Completed

Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis Patients

Anemia

United States
Watson Pharmaceuticals

Completed

Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis

Hyperhidrosis

United States
Watson Pharmaceuticals

Completed

2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.

Iron Deficiency Anemia

United States, Canada, Mexico, Bulgaria, India, Russian Federation, Croatia, Poland
Watson Pharmaceuticals

Completed

Effects of Oxybutynin Topical Gel on Gastric Emptying

Healthy

United States
Watson Pharmaceuticals

Completed

Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men

Hypogonadism

United States
Watson Pharmaceuticals

Completed

Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis Patients

Anemia

United States, Poland, Mexico, Serbia, Russian Federation
Watson Pharmaceuticals

Completed

A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia

Prostatic Hyperplasia | Nocturia

United States
Watson Pharmaceuticals

Completed

Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy

Anemia

United States
Watson Pharmaceuticals

Completed

Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition

Detrusor Hyperreflexia

United States
Watson Pharmaceuticals

Completed

Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder (MATRIX)

Quality of Life | Overactive Bladder | Urinary Incontinence

United States
Watson Pharmaceuticals

Completed

A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo

Benign Prostatic Hyperplasia (BPH)

United States
Watson Pharmaceuticals

Completed

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

Overactive Bladder

United States
Watson Pharmaceuticals

Completed

The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months

Benign Prostatic Hyperplasia

United States
Watson Pharmaceuticals

Completed

A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo

Benign Prostatic Hyperplasia

United States
Watson Pharmaceuticals
Massachusetts General Hospital

Completed

A Comparison of Patch vs. Pill Estrogen Therapy on Testosterone Levels and Thyroid Tests in Menopausal Women

Menopause

United States
University of Rochester
Watson Pharmaceuticals

Terminated

Low-Intensity Physical Therapy for Prevention of Pre and Postpartum Urinary Incontinence

Urinary Incontinence

United States
Red Rock Fertility Center
Watson Pharmaceuticals

Unknown

Examination of Serum Progesterone Levels in an IVF Population Following Two Types of Egg Aspiration

Infertility, Female

United States
Eastern Virginia Medical School
Watson Pharmaceuticals

Completed

Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole

Polycystic Ovary Syndrome

United States
Pharmatech
Watson Pharmaceuticals; Manyak, Michael, M.D.

Terminated

Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer

Prostate Cancer

United States
Kremers Urban Development Company
Watson Pharmaceuticals

Completed

Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex® 50 mg Tablet in Healthy Subjects Under Fed Conditions

Healthy

Canada
Children's Hospital Medical Center, Cincinnati
Watson Pharmaceuticals

Completed

Triptorelin for Ovary Protection in Childhood Onset Lupus

Systemic Lupus Erythematosus

United States, Brazil
Jason Wilson

Recruiting

DSUVIA in Patients With SCD VOC Present in the ED

Sickle-Cell Disease With Crisis

United States
Leonard S. Marks, M.D.
Watson Pharmaceuticals; Solvay Pharmaceuticals

Completed

Study to Determine the Effects of Testosterone Replacement Therapy in Aging Men With Androgen Deficiency

Men With Low Testosterone Levels

United States
Jason Chui

Recruiting

Cerebral Flow-metabolism Coupling During Adult Surgery

Anesthesia

Canada
Watson Laboratories, Inc.

Completed

Evaluate Therapeutic Equivalence and Safety of Two Clindamycin Phosphate and Benzoyl Peroxide Gels in Acne Vulgaris

Acne Vulgaris
Lawson Health Research Institute
Novartis Pharmaceuticals

Terminated

Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma

Scleroderma

Canada
Lawson Health Research Institute
Novartis Pharmaceuticals

Completed

Lucentis to Treat Pigment Epithelial Detachment

Pigment Epithelial Detachment

Canada
Lawson Health Research Institute
Alexion Pharmaceuticals, Inc.

Active, not recruiting

Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS

Transient Ischemic Attack | Paroxysmal Nocturnal Hemoglobinuria | Cerebral Vein Thrombosis | Embolic Stroke of Undetermined Source

Canada
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Actavis Inc.
Watson Laboratories, Inc.

Completed

Clinical Equivalence Study of Mometasone Nasal Spray

Seasonal Allergic Rhinitis

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

RSV Infection

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands

Clinical Trials Sponsored by Watson Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations